Stocksigma LogoStocksigma Logo

Tatva Chintan Updates Investor Presentation Following Metric Corrections

Tatva Chintan Pharma Chem Limited released an updated investor presentation on 19th Oct'26, rectifying typographical errors on page 12 for H1FY27 metrics

Tatva Chintan Updates Investor Presentation Following Metric Corrections

Tatva Chintan Pharma Chem Ltd · Investor Presentation · 20 Oct 2026, 2:46 am

Tatva Chintan Updates Investor Presentation Following Metric Corrections Tatva Chintan Pharma Chem Limited released an updated investor presentation on 19th Oct'26, rectifying typographical errors on page 12 for H1FY27 metrics: RoE is corrected to 6.3% (previously 2.6%) and annualized Debt-to-EBITDA is adjusted to 1.16x (previously 4.30x). All other financial figures remain unchanged. In Q2FY27, revenue from operations grew 76% YoY (30% QoQ) to ₹2,173 Mn, EBITDA reached ₹407 Mn (up 83% YoY), and PAT surged 116% YoY to ₹215 Mn, despite temporary headwinds from elevated solvent prices and freight costs.

Original exchange filing (PDF)

More announcements from Tatva Chintan Pharma Chem Ltd

All Tatva Chintan Pharma Chem Ltd announcements